Companies › Solid Biosciences
4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Neurology, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SGT-003 Adeno-associated virus serotype SLB101 gene therapy delivering human microdystrophin gene | DMD | Phase 3 | Duchenne Muscular Dystrophy | May 2027 |
| SGT-001 AAV9 vector-mediated microdystrophin gene transfer | DMD | Phase 1 | Duchenne Muscular Dystrophy | Nov 2026 |
| SGT-501 Gene therapy for ryanodine receptor 2 (RYR2) deficiency | RYR2 | Phase 1 | Catecholaminergic Polymorphic Ventricular Tachycardia | Jun 2027 |
| SGT-212 Adeno-associated virus serotype AAVhu68 containing codon-optimized complementary DNA for F | FXN | Phase 1 | Friedreich's Ataxia (FA) | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03368742 | SGT-001 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Nov 2026 |
| NCT06138639 | SGT-003 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | May 2027 |
| NCT07148089 | SGT-501 | Phase 1 | Catecholaminergic Polymorphic Ventricular Tachycardia | Cardiovascular | Jun 2027 |
| NCT07180355 | SGT-212 | Phase 1 | Friedreich's Ataxia (FA) | Neurology | Mar 2028 |
| NCT07160634 | SGT-003 | Phase 3 | Duchenne Muscular Dystrophy | Neurology | Jan 2029 |
Cash and short-term investments of $349m on 2026-09-30; operating cash outflow about $195m a year; runway about 22 months at that burn, to Jul 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
NS Pharma Larimar Therapeutics Denali Therapeutics Dyne Therapeutics Coya Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.